HR Execs on the Move

Invitae

www.invitae.com

 
Invitae is a leader in medical genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world`s medical genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.invitae.com
  • 1400, 16th Street
    San Francisco, CA USA 94103
  • Phone: 415.374.7782

Executives

Name Title Contact Details
Ana Schrank
Chief Financial Officer Profile
Robert Dickey
Interim Chief Financial Officer Profile
Robert Dickey
Interim Chief Financial Officer Profile
Matt Willmon
Vice President, Total Rewards Profile
Eric Olivares
Head of Research And Development Profile

Similar Companies

ISI Interscience

ISI Interscience is a Troy, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Epitomics Inc

Epitomics Inc is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BlueWillow Biologics

NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.

Global BioChem

Global BioChem is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cedilla Therapeutics

We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.